Timber Pharmaceuticals and BioPharmX Corp. inks merger agreement
Category: #health  By Saipriya Iyer  Date: 2020-01-30
  • share
  • Twitter
  • Facebook
  • LinkedIn

Timber Pharmaceuticals and BioPharmX Corp. inks merger agreement

A specialty pharmaceutical company, BioPharmX Corporation and a privately held biopharmaceutical company, Timber Pharmaceuticals LLC, which is focused on developing and commercializing treatments for orphan dermatologic diseases, recently announced to have inked a definitive merger agreement.

Under the terms of the agreement, subject to the approval of Timber's members and BioPharmX's stockholders, a fully--owned subsidiary of BioPharmX will be merged with Timber and Timber pharmaceuticals will be operating as a wholly-owned subsidiary of BioPharmX.

Timber has agreed to secure not less than USD 20 million of financing for the combined company, as per a condition to the closing of the Merger. The merger is expected to be completed by the mid of 2020, and upon its completion, BioPharmX will change its name to Timber Pharmaceuticals, Inc. Also, the directors and officers of Timber will become the officers and directors of BioPharmX.

John Koconis, CEO of Timber Pharmaceuticals was reportedly quoted saying that the team is exhilarated to reach a merger agreement with the leading specialty pharmaceutical, BioPharmX, which will provide the firm with the opportunity to trade its share in the public market once the merger is completed. The merger will help Timber expand its investor base as the firm strategically build its pipeline in rare dermatologic diseases, which have no approved treatments as yet.

Koconis, added saying that this merger will also aid in expanding the company’s resources and expertise, which will further facilitate development programs targeting new therapies for inadequately served patient pool with some of the most serious conditions in medical dermatology.

Followed by the closing of merger, the combined firm will also evaluate Phase 3 proprietary topical minocycline gel programs of BioPharmX for a co-development partnership or other non-dilutive value creation strategy. The product has already been studied by BioPharmX for the treatment of inflammatory lesions of papulopustular rosacea and acne vulgaris.
 

Source Credit: https://www.prnewswire.com/news-releases/biopharmx-and-timber-pharmaceuticals-announce-entry-into-merger-agreement-300994838.html



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Medtronic to turn Hyderabad into R&D hub with $160.3M investment
Medtronic to turn Hyderabad into R&D hub with $160.3M investment
By Saipriya Iyer

Medtronic, a medical device company, has reportedly announced an investment of Rs.1,200 crore ($160.3 million) to turn Hyderabad into its R&D center outside the U.S. The investment has been planned by the company s...

Toshiba exits PC business & transfers remaining 19.1% stake to Sharp
Toshiba exits PC business & transfers remaining 19.1% stake to Sharp
By Saipriya Iyer

Toshiba, a Japanese multinational conglomerate, has reportedly made an exit from the laptop business and transferred its remaining minority stake in the PC business to Sharp. This will mark the company’s terminat...

Montero inks agreement to acquire Isabella Gold Silver Project
Montero inks agreement to acquire Isabella Gold Silver Project
By Saipriya Iyer

Montero Mining and Exploration Ltd. has reportedly inked a Binding Purchase & Sale Agreement to acquire a 100% or full interest in a private company in Chile. ChileCo holds several mineral rights to exploration cla...